编 辑丨朱益民 大河奔流，潮立中天。 今 年 以 来 ， A 股 江 湖 风 雷 激 荡 ， 一 方 面 ， 关 税 扰 动 下 不 确 定 性 因 素 增 多 ， 另 一 方 面 ， DeepSeek引发中国资产价值重估，以成长、金融为两端的"哑铃"风格愈演愈烈。 整体来看，受益于一揽子新政影响，A股市场震荡回升。截至2025年6月30日，2025年中市值 百强榜隆重出炉， 入围企业总市值41.63万亿元，较去年同期 （截至2024年6月30日，下同） 的35.33万亿元增长17.83% 。 作 者丨杨坪 实习生宋晨曦 宁王、迪王跻身万亿 "巨龙" 俱乐部 华山之巅，科技新锐与传统豪强交锋。 从前十榜来看，央国企仍占据主要席位 ，工、农、建三大行占据前三席，贵州茅台从前二掉 到第四位，央企"巨龙"中移动、中石油分别排名第五和第七，中国银行、招商银行排名第六 和第八。 动力电池霸主宁德时代、比亚迪以迅雷不及掩耳之势突破万亿市值大关，力压中国人寿、中 国平安等金融巨子，分别跻身百强榜第九和第十席位，成为前十榜中的新面孔。 过去一年来，宁德时代、比亚迪市值涨幅分别达到了46.16%、47.64% ，截至6月30日 ...

Core Insights - The meetings held by the Hebei Securities Regulatory Bureau focused on mergers and acquisitions (M&A) policies, tax planning, and financial service innovations, with over 150 representatives from regulatory bodies, listed companies, and financial institutions attending [1][2] Group 1: M&A Policies and Trends - The revised "Management Measures for Major Asset Restructuring of Listed Companies" emphasizes policy optimization, including phased payment mechanisms, enhanced regulatory inclusiveness, simplified review processes, and support for industrial integration [1] - In the first half of 2025, A-share M&A transaction volume increased by 71% year-on-year, with 77% of transactions being industrial integration types, highlighting the dominance of control transactions, asset injections, and bankruptcy reorganizations [3] - The average review cycle for M&A has been reduced by 40%, with simplified procedures allowing for registration completion in as little as 10 working days [4] Group 2: Tax Planning and Compliance - Companies must pay attention to the handling of six major tax types during restructuring, including VAT and corporate income tax, and should plan tax arrangements in advance to mitigate potential risks [1][2] - Representatives emphasized the importance of compliance and communication with tax authorities and professional institutions throughout the M&A process, establishing a comprehensive risk control system [2] Group 3: Strategic Insights from Case Studies - Companies like Boshen Co. shared experiences from significant acquisitions, emphasizing the need for strategic alignment and enhanced management capabilities post-merger to mitigate goodwill risks [3] - The Hebei Securities Regulatory Bureau encourages listed companies, especially small and medium-sized enterprises, to leverage M&A opportunities to enhance capital operation activity and achieve industrial upgrades and strategic transformations [4]

"两船"合并，迎来重大进展！ 7月4日晚间，中国船舶公告称，当天，公司吸收合并中国重工事项获上交所审核通过。此次交易尚需中 国证监会予以注册以及其他可能涉及的必要批准、核准、备案或许可（如需）后方可正式实施。 此次重组完成后，存续公司中国船舶将成为全球最大造船上市公司，资产规模、营业收入规模、手持订 单数均领跑全球。 此次交易中，中国船舶为吸收合并方，中国重工为被吸收合并方。交易完成后，中国船舶实际控制人仍 为中国船舶集团有限公司、最终控制人仍为国务院国资委，未发生变更。 交易方案显示，中国船舶的换股价格按照定价基准日前120个交易日的股票交易均价确定为37.84元/ 股，中国重工的股票交易均价确定为5.05元/股，并由此确定中国重工与中国船舶的换股比例为 1:0.1335，即每1股中国重工股票可以换得0.1335股中国船舶股票。 审核通过 中国船舶（600150）7月4日晚公告，公司吸收合并中国重工事项获上交所审核通过。 中国船舶公告称，公司拟向中国重工全体换股股东发行A股股票的方式换股吸收合并中国重工。上交所 并购重组审核委员会于7月4日召开2025年第8次并购重组审核委员会审议会议，对公司本次交易的申请 ...

Core Viewpoint - The recent equity transfer actions of Boya Biological, a key player in China's blood products sector, have raised significant market concerns due to continuous price reductions and operational challenges [2][3]. Equity Transfer and Pricing Adjustments - Boya Biological's subsidiary, Boya Xinhao, has seen its 80% equity stake listed at a latest price of 170 million yuan, down nearly 20% from the initial listing price of 213 million yuan [2]. - This marks the third price adjustment within three months, with previous attempts at 213 million yuan and 192 million yuan failing to attract buyers [2]. - If no buyer emerges, the price may drop further to below 160 million yuan, representing a decline of over 25% from the initial listing price [2]. Financial Performance and Challenges - Boya Xinhao's financial performance has been poor, with 2023 revenue at 10.37 million yuan and a net loss of 56.87 million yuan [6]. - Despite efforts to reduce losses in 2024, revenue remained below 20 million yuan, primarily due to delays in product development and external pressures from procurement policies [6][10]. - Boya Biological's overall revenue growth has sharply declined from 5.47% in 2021 to a negative growth of -3.87% in 2023, with a further drop of 34.58% in 2024 [8][9]. Strategic Focus and Industry Context - Boya Biological emphasizes a strategic focus on blood products, aiming to optimize resource allocation by divesting non-core assets [8]. - The company aims to double its plasma collection capacity and key financial metrics during the 14th Five-Year Plan period (2021-2025) [6]. - The blood products industry faces challenges such as tight plasma supply and expanding procurement ranges, which may further compress operational space for companies [2][10]. Market Dynamics and Future Outlook - The blood products sector is undergoing significant changes, with increasing regulatory scrutiny and market competition leading to a consolidation trend [11]. - Boya Biological's recent actions reflect a broader industry shift towards specialization and the need for sustainable competitive advantages amid evolving market conditions [11][12].

Group 1 - The core point of the article is that Guotou Zhonglu plans to acquire 100% of the China Electronic Engineering Design Institute, marking its entry into the electronic engineering sector [1][2][3] - The acquisition will be executed through a share issuance to several investors, including Guotou Group and others, and is expected to constitute a major asset restructuring [2][3] - This strategic move aims to transform Guotou Zhonglu's business from concentrated fruit juice production to include industrial consulting, process design, engineering construction, and smart factory solutions [3][4] Group 2 - The transaction is anticipated to enhance Guotou Zhonglu's asset scale, operating income, and net profit attributable to shareholders [4] - In recent years, Guotou Zhonglu has faced significant performance pressure, with a revenue decline of 13.89% in 2023 to 1.487 billion yuan and a net profit drop of 36.79% to 58.22 million yuan [5][6] - However, the company reported a strong recovery in Q1 2025, with a revenue increase of 58.03% to 573 million yuan and a net profit surge of 217.54% to 27.01 million yuan, attributed to higher customer order demand [6]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 证券停复牌情况：适用 因筹划重大资产重组事项，本公司的相关证券停复牌情况如下： 证券代码：600962 证券简称：国投中鲁 公告编号：2025-038 国投中鲁果汁股份有限公司 关于发行股份购买资产并募集配套资金暨关联交易的 一般风险提示暨公司股票复牌的公告 证券代码 证券简称 停复牌类型 停牌起始日 停牌 停牌终止日 复牌日 期间 次发行股份购买资产并募集配套资金暨关联交易具体方案的议案》《关于 <国投中> 鲁果汁股份有限公司发行股份购买资产并募集配套资金暨关联交易预案>及其摘 要的议案》等相关议案，《国投中鲁果汁股份有限公司发行股份购买资产并募集 配套资金暨关联交易预案》及其摘要的具体内容详见公司于 2025 年 7 月 5 日在上 海证券交易所网站（www.sse.com.cn）及指定媒体披露的相关公告。根据相关规 定，经公司向上海证券交易所申请，公司股票（股票简称：国投中鲁，股票代码： 截至本公告披露日，本次交易涉及资产的审计、评估工作尚未完成，公司董 ...

证券代码：603031 证券简称：安孚科技 公告编号：2025-054 安徽安孚电池科技股份有限公司（以下简称"公司"）拟以发行股份及支付 现金的方式购买宁波九格众蓝股权投资合伙企业（有限合伙）、袁莉、华芳集团 有限公司、张萍、钱树良和安徽金通新能源汽车二期基金合伙企业（有限合伙） 持有的安徽安孚能源科技有限公司（以下简称"标的公司"）31.00%的股权，同 时，公司拟向不超过 35 名特定对象发行股份募集配套资金（以下简称"本次交 易"）。 安徽安孚电池科技股份有限公司 关于上海证券交易所并购重组审核委员会审核公司 发行股份及支付现金购买资产并募集配套资金暨 关联交易事项会议安排的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次交易尚需经上交所审核通过及中国证券监督管理委员会同意注册后方 可实施。本次交易能否通过审核、取得注册，以及最终通过审核、取得注册的时 间均存在不确定性，本公司将根据审核进展情况及时履行信息披露义务，敬请广 大投资者关注后续公告并注意相关投资风险。 特此公告。 安徽安孚电池科技股份有限公司董事 ...

证券代码：301079 证券简称：邵阳液压 公告编号：2025-040 邵阳维克液压股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 邵阳维克液压股份有限公司（以下简称"公司"或"上市公司"）第六届董 事会第四次会议于 2025 年 7 月 4 日（星期五）10:00 在公司会议室以现场会议 的方式召开。本次会议的通知已于 2025 年 7 月 1 日通过微信、电话或电子邮件 方式送达全体董事。会议由董事长粟武洪先生召集并主持，应出席董事 5 人，实 际出席董事 5 人。公司高级管理人员列席会议。 本次会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司 法》"）等法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定， 会议合法、有效。 二、董事会会议审议情况 会议经与会董事认真审议，并以书面表决方式通过以下议案： 金暨关联交易条件的议案》 公司拟发行股份及支付现金购买重庆新承航锐科技股份有限公司（以下简称 "新承航锐"）100%的股份（以下简称"标的资产"）并募集配套资金暨关联交 易（以下简称"本次交易" ...

Core Viewpoint - The company plans to acquire 100% of Chongqing Xincheng Hangrui Technology Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds [1][2] Group 1: Transaction Details - The transaction involves 38 counterparties, including Ling Jun and Deng Hongxin, who hold the shares of Xincheng Hangrui [1] - The company has conducted a thorough analysis to ensure compliance with the regulatory requirements outlined in the "Guidelines for the Supervision of Listed Companies on Major Asset Restructuring" [1][2] - The company will hold 100% of Xincheng Hangrui after the transaction, making it a wholly-owned subsidiary [1] Group 2: Regulatory Compliance - The board has confirmed that the transaction meets the regulatory requirements, specifically the fourth article of the relevant guidelines [2] - The company has disclosed all necessary approval procedures in the asset acquisition plan and highlighted potential risks related to obtaining approvals [1][2] - The transaction is expected to enhance the company's main business focus and improve its risk resistance capabilities [2]

及其摘要和本次交易需要提交的其他有关文件。 邵阳维克液压股份有限公司董事会 关于本次重组履行法定程序的完备性、合规性及 提交法律文件的有效性的说明 邵阳维克液压股份有限公司（以下简称"公司"）拟通过发行股份及支付 现金方式购买凌俊、邓红新等38名交易对方持有的重庆新承航锐科技股份有限 公司（以下简称"新承航锐"）100%股份并募集配套资金（以下简称"本次重 组"）。本次重组完成后，新承航锐将成为公司的全资子公司。 根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所 创业板股票上市规则》《上市公司重大资产重组管理办法》《上市公司监管指引第 信息披露内容与格式准则第 26 号——上市公司重大资产重组》等法律法规和规 范性文件的规定，公司董事会就本次交易履行法定程序的完备性、合规性及提交 法律文件的有效性进行如下说明： 一、关于本次交易履行法定程序完备性、合规性的说明 采取了必要且充分的保密措施，并严格限定本次交易相关敏感信息的知悉范围。 制作《内幕信息知情人登记表》及《重大事项进程备忘录》，经相关人员签字确 认后向深圳证券交易所进行了报送。 月 23 日开市起停牌，预计停牌时间不超过 10 个交 ...